We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13.00 | 4.53% | 300.00 | 298.50 | 301.50 | 304.50 | 280.50 | 280.50 | 325,249 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -6.43 | 290.22M |
From May 2019 to May 2024
By Philip Waller
LONDON--Gene and cell therapy group Oxford Biomedica PLC (OXB.LN) Thursday posted a wider 2016 loss, though it forecasted progress with core technology and new partnerships in 2017.
Oxford said its loss in the year to Dec. 31 rose to 20.3 million pounds ($24.9 million) from GBP16.9 million a year earlier despite higher revenue of GBP27.8 million, up from GBP15.9 million.
The company attributed the wider loss to higher depreciation, amortization and share-option charges as well as interest charges inflated by the weakness of sterling against the dollar.
The company said its oss before interest, taxes, depreciation and amortization fell to GBP7.1 million from GBP12.1 million.
Oxford said its work with Switzerland's Novartis was progressing well, with potential blockbuster cancer treatment CTL019 close to market.
Chief Executive John Dawson said: "Beyond Novartis, we have added new revenue-generating partnerships and collaborations during 2016 which are progressing well and are confident we can add further relationships during 2017."
-Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
March 16, 2017 03:43 ET (07:43 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
